Healthsens is currently developing the only immunological POCT (Point of Care Testing) device that will allow the early and non-invasive diagnosis of prostate cancer. Healthsens Prostasens is a biotechnological innovation that will be able to calculate the prostate health index (PHI), which will allow patients to control their disease, changing the lives of millions of people. 

Healthsens is developing a low-cost, portable point-of-care testing (POCT) device that will quantify three biomarkers associated with prostate cancer in a single drop of serum. The final measuring device shall be an electrochemical sensor, consisting of three electrodes, which shall allow the simultaneous determination and with a high degree of accuracy of total PSA, free PSA and [-2]proPSA.

Unlike the methods commonly used in clinical practice, Healthsens Prostasens® will allow, in a simple and non-invasive way, to obtain comprehensive information on the probability of developing prostate cancer in patients, not only provide an isolated concentration value, but also calculate the prostate health index (PHI).

PHI, calculated from total serum PSA concentration, free PSA, and [-2]proPSA, is a multivariate index that indicates the presence of a tumor and its stage of development, as well as degree of aggressiveness. The use of PHI is approved in Europe, USA (FDA) and Australia.

The commercialization of the Healthsens Prostasens® device aims to facilitate the early diagnosis of prostate cancer, so that it is accessible to patients.  Healthsens Prostasens‍ will allow to carry out population screening quickly and easily, without the need for rectal examinations or biopsies, and all at a very low cost.


Prostate cancer is the most common type of cancer among the male population, increasing its incidence and mortality with age. About 1 in 8 men will be diagnosed with prostate cancer in their lifetime.


According to data from the Spanish Association of Urology (AEU), one and a half million Spanish men, aged between 50 and 75 years, are at risk for prostate cancer.


Prostate cancer is the third leading cause of cancer death in men. Globally, 2.8 per cent of all deaths among men are due to this disease. Every year in Spain there are 3,600 deaths due to this pathology.

Do you need more information?

Please feel free to contact us for more information on HEALTHSENS.

(+34) 985 232 428